Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
25%(2 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_4
4
33%
Ph phase_1
2
17%
Ph phase_2
1
8%
Ph phase_3
2
17%
Ph not_applicable
2
17%

Phase Distribution

2

Early Stage

1

Mid Stage

6

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
1(9.1%)
Phase 3Large-scale testing
2(18.2%)
Phase 4Post-market surveillance
4(36.4%)
N/ANon-phased studies
2(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(8)
Terminated(3)
Other(1)

Detailed Status

Completed8
Terminated2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (18.2%)
Phase 21 (9.1%)
Phase 32 (18.2%)
Phase 44 (36.4%)
N/A2 (18.2%)

Trials by Status

completed867%
unknown18%
withdrawn18%
terminated217%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_3

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02814916
withdrawnphase_4

Penicillin Against Flucloxacillin Treatment Evaluation

NCT03632642
completednot_applicable

Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital

NCT02334124
completedphase_4

Adjunctive Clindamycin for Cellulitis: C4C Trial.

NCT01876628
completedphase_1

Flucloxacillin as an Inducer of CYP-enzymes

NCT04840641
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT02814916Phase 3

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Completed
NCT03632642Phase 4

Penicillin Against Flucloxacillin Treatment Evaluation

Withdrawn
NCT02334124Not Applicable

Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital

Completed
NCT01876628Phase 4

Adjunctive Clindamycin for Cellulitis: C4C Trial.

Completed
NCT04840641Phase 1

Flucloxacillin as an Inducer of CYP-enzymes

Completed
NCT01792804Phase 3

Staphylococcus Aureus Bacteremia Antibiotic Treatment Options

Completed
NCT00433342Phase 1

The Effect of Antimicrobial Therapy on the Serum Level of P-cresol in Peritoneal Dialysis Patients

Terminated
NCT02993575

Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients

Completed
NCT00428844Phase 2

Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci

Completed
NCT02032654Phase 4

Duration of ANtibiotic Therapy for CEllulitis

Terminated
NCT02922686Phase 4

Penicillin for the Emergency Department Outpatient Treatment of CELLulitis

Unknown
NCT00405158Not Applicable

Study of Acupuncture and Care Interventions for the Treatment of Breast Inflammation During Breastfeeding

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12